Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 1, 2011, Pages 74-77

  Giegling, Ina ^a   Drago, Antonio ^b   Schäfer, Martin ^a,c   Möller, Hans Jürgen ^a   Rujescu, Dan ^a   Serretti, Alessandro ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c KLINIKEN ESSEN MITTE   (Germany)

Author keywords

Haloperidol; Motor side effects; Predictors

Indexed keywords

HALOPERIDOL;

ACUTE PSYCHOSIS; ADULT; AGING; ARTICLE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PREDICTION; RATING SCALE; RISK ASSESSMENT; SAMPLE SIZE; SEX DIFFERENCE;

ADULT; ANTIPSYCHOTIC AGENTS; DEMOGRAPHY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; STATISTICS AS TOPIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650935402     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.08.029     Document Type: Article

References (11)

1. Addonizio G., Alexopoulos G.S. Drug-induced dystonia in young and elderly patients. Am J Psychiatry 1988, 145:869-871.
2. Aguilar E.J., Keshavan M.S., Martinez-Quiles M.D., Hernandez J., Gomez-Beneyto M., Schooler N.R. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994, 151:1819-1821.
3. Chouinard G., Margolese H.C. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005, 76:247-265.
4. Giegling I., Drago A., Schafer M., Moller H.J., Rujescu D., Serretti A. Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. J Psychiatr Res 2009, 44(8):487-492.
5. Goff D.C., Arana G.W., Greenblatt D.J., Dupont R., Ornsteen M., Harmatz J.S., et al. The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. J Clin Psychopharmacol 1991, 11:106-112.
6. Jeste D.V., Lindamer L.A., Evans J., Lacro J.P. Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacol Bull 1996, 32:243-251.
7. Joy C.B., Adams C.E., Lawrie S.M. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev 2006, CD003082.
8. Masand P.S. Side effects of antipsychotics in the elderly. J Clin Psychiatry 2000, 61(Suppl 8):43-49. discussion 50-1.
9. Moleman P., Schmitz P.J., Ladee G.A. Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics. J Clin Psychiatry 1982, 43:492-496.
10. Swett C. Drug-induced dystonia. Am J Psychiatry 1975, 132:532-534.
11. Waraich P.S., Adams C.E., Roque M., Hamill K.M., Marti J. Haloperidol dose for the acute phase of schizophrenia. Cochrane Database Syst Rev 2002, CD001951.